Vorapaxar: targeting a novel antiplatelet pathway
- PMID: 22346324
- PMCID: PMC3278139
Item in Clipboard
Vorapaxar: targeting a novel antiplatelet pathway
P T.
2011 Sep.
No abstract available
Figures
Chemical structure of vorapaxar. (From the National Center for Biotechnology Information, National Institutes of Health.9)
Similar articles
-
Vorapaxar expands antiplatelet options.Hamostaseologie. 2012;32(3):221-227. doi: 10.5482/HAMO-12-05-0006. Epub 2017 Dec 28. Hamostaseologie. 2012. PMID: 29589363 English.
-
Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar.Cardiology. 2016;133(2):69-72. doi: 10.1159/000440798. Epub 2015 Oct 22. Cardiology. 2016. PMID: 26488178 Clinical Trial.
-
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.J Thromb Thrombolysis. 2019 Apr;47(3):353-360. doi: 10.1007/s11239-018-1779-y. J Thromb Thrombolysis. 2019. PMID: 30511258 Clinical Trial.
-
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis.Ther Clin Risk Manag. 2015 Aug 3;11:1133-8. doi: 10.2147/TCRM.S55469. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 26346960 Free PMC article. Review.
-
Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial.Int J Stroke. 2016 Aug;11(6):614-7. doi: 10.1177/1747493016632253. Epub 2016 Feb 9. Int J Stroke. 2016. PMID: 26860124 Review.
Cited by
-
Molecular Insights into the Relationship Between Platelet Activation and Endothelial Dysfunction: Molecular Approaches and Clinical Practice.Mol Biotechnol. 2024 May;66(5):932-947. doi: 10.1007/s12033-023-01010-8. Epub 2024 Jan 6. Mol Biotechnol. 2024. PMID: 38184492 Review.
-
Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?Int J Mol Sci. 2019 Nov 11;20(22):5629. doi: 10.3390/ijms20225629. Int J Mol Sci. 2019. PMID: 31717963 Free PMC article. Review.
-
Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?Ann Transl Med. 2018 Feb;6(3):56. doi: 10.21037/atm.2017.11.36. Ann Transl Med. 2018. PMID: 29610748 Free PMC article. No abstract available.
-
Gestodene, a novel positive allosteric modulator of PAR1, enhances PAR1-mediated human platelet aggregation.Front Pharmacol. 2024 Jul 26;15:1430548. doi: 10.3389/fphar.2024.1430548. eCollection 2024. Front Pharmacol. 2024. PMID: 39130626 Free PMC article.
-
Blood thinners and gastrointestinal endoscopy.World J Gastrointest Endosc. 2016 Sep 16;8(17):584-90. doi: 10.4253/wjge.v8.i17.584. World J Gastrointest Endosc. 2016. PMID: 27668068 Free PMC article. Review.
References
-
- Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST segment elevation myocardial infarction. J Am Coll Cardiol. 2007;50:1–157. - PubMed
-
- The TRA·CER Executive and Steering Committees The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA·CER) trial: Study design and rationale. Am Heart J. 2009;158:327–334. - PubMed
-
- Bridgewater, N.J.: Bristol Meyers Squibb/Sanofi Pharmaceuticals Partnership; Feb, 2011. Plavix, package insert.
-
- Goto S, Yamaguchi T, Ikeda Y, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb. 2010;17:156–164. - PubMed
-
- Macaulay TE, Allen C, Ziad KM. Thrombin receptor antagonism: The potential of antiplatelet medication SCH 530348. Exp Opin Pharmacother. 2010;11:1015–1022. - PubMed
LinkOut - more resources
Full Text Sources